Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Cash from Operations (2016 - 2025)

Immucell's Cash from Operations history spans 16 years, with the latest figure at 482541.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 15915.83% year-over-year to 482541.0; the TTM value through Dec 2025 reached 2475292.0, up 591.61%, while the annual FY2025 figure was 2475292.0, 591.61% up from the prior year.
  • Cash from Operations reached 482541.0 in Q4 2025 per ICCC's latest filing, up from 1182583.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 1601498.0 in Q2 2025 to a low of 2761985.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 121537.1, with a median of 127970.0 recorded in 2021.
  • Peak YoY movement for Cash from Operations: crashed 585.75% in 2022, then skyrocketed 15915.83% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 587893.0 in 2021, then tumbled by 320.76% to 1297822.0 in 2022, then soared by 44.29% to 723071.0 in 2023, then surged by 99.58% to 3051.0 in 2024, then surged by 15915.83% to 482541.0 in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Cash from Operations are 482541.0 (Q4 2025), 1182583.0 (Q3 2025), and 1601498.0 (Q2 2025).